Hinge Health

HNGE · NYSE

$107.51+$3.55 (+3.41%)TodayMarket closed ·
Prev close $103.96

About HNGE

Hinge Health, Inc. is a digital healthcare company, which engages in software for joint and muscle health care. The company is headquartered in San Francisco, California and currently employs 1,437 full-time employees. The company went IPO on 2025-05-22. The firm has designed its TrueMotion platform to address a spectrum of musculoskeletal (MSK) care from acute injury to chronic pain, to post-surgical rehabilitation. Members receive personalized and automated MSK care through its AI-powered motion tracking technology. The company offers electrical nerve stimulation wearable device Enso, all designed and monitored by its AI-supported care team of licensed physical therapists, physicians, and board-certified health coaches. Its platform offers a range of support with multiple programs across many affected areas to provide a continuum of care from prevention to treatment of acute injury and chronic pain, as well as surgery decision support and post-surgical recovery. Enso delivers electrical nerve stimulation designed to provide non-addictive and non-invasive pain relief.

Employees
1,437
Headquarters
San Francisco, California
Listed
May 22, 2025
Sector
Health Care
Industry
Health Care Providers & Services

HNGE key statistics

Market cap
8.68B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.66M
Volume
4.09M
Open price
$103.64
High today
$108.00
Low today
$103.30
52 Week high
$107.00
52 Week low
$30.08

Hinge Health (HNGE) at a glance

As of Oct 20, 2026, Hinge Health (HNGE) shares are priced at $107.51, giving the company a market cap of 8.68B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $103.30 and $108.00. The current price is 4.1% above the day's low and 0.5% below its high.

Volume so far is 4.09M shares, above the average of 1.66M shares a day.

Over the past year Hinge Health has ranged from $30.08 to $107.00, and now sits 101% of the way up that range.

Hinge Health met or beat analyst EPS estimates in 4 of the last 5 quarters. In Q2 FY26 it reported $0.59 per share against an estimate of $0.6014.

The average analyst price target is $111.50, 3.7% above the current price, from 15 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

93%of 15 analyst ratings say Buy
  • Buy93.3%
  • Hold6.7%
  • Sell0.0%
Price target · 18 analystsAvg $111.50
Low
$90.90
Now
$107.51
High
$147.00

HNGE earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 5 quarters, by 208.5% on average.

  1. Q2 FY25: reported $0.708 per share against an estimate of $0.0881
  2. Q3 FY25: reported $0.44 per share against an estimate of $0.229
  3. Q4 FY25: reported $0.49 per share against an estimate of $0.4018
  4. Q1 FY26: reported $0.45 per share against an estimate of $0.3869
  5. Q2 FY26: reported $0.59 per share against an estimate of $0.6014

HNGE news

  • 'Hinge Health Sees Hardware Deals Ahead in Digital Health Push'- Bloomberg

  • Press releaseBusiness Wire

    Hinge Health to announce third quarter 2026 financial results on November 2, 2026

  • Avi Kapoor

    Jim Cramer: Buy This Energy Stock, It Is ‘Terrific’

  • Caroline Ryan

    Oura Reportedly Eyes $3 Billion IPO at More Than $16 Billion Valuation

  • Press releaseBusiness Wire

    Hinge Health to acquire Cylinder Health, expanding into gastrointestinal care

  • Press releaseBusiness Wire

    Hinge Health reports record second quarter 2026 financial results; signs definitive agreement to acquire Cylinder Health

  • Press releaseBusiness Wire

    Study finds Hinge Health significantly lowers fall risk for adults aged 65+

  • Press releaseBusiness Wire

    Hinge Health to announce second quarter 2026 financial results on August 4, 2026

Similar companies

Companies in the same industry as Hinge Health

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.